Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
Objective Turoctocog alfa is a recombinant factor VIII (rFVIII) for the prevention and treatment of bleeding in patients with hemophilia A, including those undergoing surgery and invasive medical procedures. This in vitro study evaluated the physical and chemical stability of turoctocog alfa during continuous infusion (CI) over 24 hours at 30°C.
Materials and Methods The study was performed at 30°C ( ± 2°C). A CI system with pump speed set at either 0.6 or 1.5 mL/h was used to evaluate the stability of three turoctocog alfa strengths (500, 1,000, and 3,000 IU), equating to doses of 1.1 to 16.1 IU/h per kilogram of body weight. The following parameters were evaluated at selected time points between 0 and 24 hours: appearance of solution, clarity, pH, potency, purity, content, total high molecular weight proteins (HMWPs), and oxidized rFVIII.
Results The mean potency of turoctocog alfa was maintained within the predefined acceptance criteria during CI for both pump speeds with all three strengths at 6, 12, or 24 hours (500 IU: ≥484 IU/vial; 1,000 IU: ≥1,014 IU/vial; and 3,000 IU: ≥3,029 IU/vial). Furthermore, the appearance of solution, clarity, pH, purity, content of turoctocog alfa, total HMWP, and oxidized forms were also within the predefined limits, and comparable to the reference samples (time = 0 hours) for the pump speeds and product strengths assessed.
Conclusion Physical and chemical stability of turoctocog alfa was maintained during CI over 24 hours. There was only minor degradation or changes in any of the parameters tested. Potency was within the prespecified acceptance limits throughout 24 hours of infusion. These findings confirm the suitability of turoctocog alfa for CI.
This work was presented in abstract form at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders, Prague, Czech Republic, February 6 to 8, 2019.
All authors contributed to analysis and/or interpretation of data, critical writing, or revising the intellectual content and final approval of the manuscript.
Received: 31 March 2020
Accepted: 23 September 2020
06 November 2020 (online)
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Chevalier Y, Dargaud Y, Lienhart A, Chamouard V, Negrier C. Seventy-two total knee arthroplasties performed in patients with haemophilia using continuous infusion. Vox Sang 2013; 104 (02) 135-143
- 2 Soucie JM, Cianfrini C, Janco RL. et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103 (07) 2467-2473
- 3 Srivastava A, Brewer AK, Mauser-Bunschoten EP. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
- 4 Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110 (03) 715-720
- 5 Martinowitz U, Luboshitz J, Bashari D. et al. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Haemophilia 2009; 15 (03) 676-685
- 6 Meijer K, Rauchensteiner S, Santagostino E. et al. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A. Haemophilia 2015; 21 (01) e19-e25
- 7 Park YS, Shin WJ, Kim KI. Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia. BMC Musculoskelet Disord 2017; 18 (01) 356
- 8 Takedani H. Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII. Haemophilia 2010; 16 (05) 740-746
- 9 Takeyama M, Nogami K, Kobayashi R. et al. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report. Int J Hematol 2018; 108 (02) 199-202
- 10 Shields S, Kim A, Elder J. Extended stability and sterility of antihemophilic factor human. J Pediatr Pharmacol Ther 2017; 22 (03) 203-206
- 11 Brand-Staufer B, Dahl PW, Johansen SD, Nøhr AM. Turoctocog alfa is stable during storage at 40°C and multiple sequences of temperature cycling. Abstract number: M‐P‐052. Presented at World Federation of Haemophilia Congress, May 20–24, 2018. Haemophilia 2018; 24 (S5): 30
- 12 Fernandez M, Yu T, Bjornson E, Luu H, Spotts G. Stability of ADVATE, antihemophilic factor (recombinant) plasma/albumin-free method, during simulated continuous infusion. Blood Coagul Fibrinolysis 2006; 17 (03) 165-171
- 13 Batorova A, Holme P, Gringeri A. European Haemophilia Treatment Standardisation Board. et al. Continuous infusion in haemophilia: current practice in Europe. Haemophilia 2012; 18 (05) 753-759
- 14 Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia 2018; 24 (01) 24-32
- 15 New Zealand data sheet. Available at: https://www.medsafe.govt.nz/profs/Datasheet/a/advateinj.pdf. Accessed October 9, 2020
- 16 Tiede A, Klamroth R, Oldenburg J. Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results. Hamostaseologie 2015; 35 (04) 364-371
- 17 NovoEight: summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/novoeight-epar-product-information_en.pdf. Accessed October 9, 2020
- 18 Santagostino E, Lentz SR, Misgav M. et al. Safety and efficacy of turoctocog alfa (NovoEight) during surgery in patients with haemophilia A: results from the multinational guardian clinical trials. Haemophilia 2015; 21 (01) 34-40
- 19 Kulkarni R, Karim FA, Glamocanin S. et al. Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19 (05) 698-705
- 20 Lentz SR, Misgav M, Ozelo M. et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19 (05) 691-697
- 21 Skands ARH, Engelund DK, Rossmeisl CC, Sejling K. Stability of Turoctocog Alfa, a New rFVIII Product from Novo Nordisk, When Stored at High Temperature and Humidity. Haemophilia 2014; 20 (Suppl. 03) 176
- 22 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline Quality of biotechnological products: stability testing of biotechnological/biological products. November 30, 1995 Accessed October 20, 2020 at: https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf
- 23 European Pharmacopoeia 2.2.1, Physical and physicochemical methods, Clarity and degree of opalescence of liquids. Available at: https://www.drugfuture.com/Pharmacopoeia/EP7/DATA/20201E.PDF. Accessed January 21, 2020
- 24 European Pharmacopoeia 2.2.3, Potentiometric determination of pH. Available at: http://www.uspbpep.com/ep50/2.2.3.%20Potentiometric%20determination%20of%20pH.pdf. Accessed January 21, 2020
- 25 US Pharmacopeia, <791> pH. Available at: http://www.uspbpep.com/usp29/v29240/usp29nf24s0_c791.html. Accessed November 28, 2018
- 26 Japanese Pharmacopoeia, Japanese Pharmacopoeia 17th Edition. https://www.pmda.go.jp/english/rs-sb-std/standards-development/jp/0019.html. Accessed January 21, 2020
- 27 European Pharmacopoeia 2.7.4, Assay of human coagulation factor VIII. Available at: https://www.biotoxik.it/wp-content/uploads/2017/11/20704E-Assay-of-Human-Coagulation-FVIII.pdf. Accessed January 21, 2020
- 28 Revel-Vilk S, Blanchette VS, Schmugge M, Clark DS, Lillicrap D, Rand ML. In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A. Haemophilia 2010; 16 (01) 72-79
- 29 Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica 2013; 98 (09) 1481-1486
- 30 Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 2012; 157 (06) 653-663
- 31 Shim YJ, Lee KS, Kim UH, Suh JK, Baik SY, Hyun SY. Progress of in vitro factor VIII coagulant activity from 0 to 8 hours after reconstitution. Blood Res 2014; 49 (04) 265-269